177Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases

Journal of Nuclear Medicine Technology

Volumn 42, Issue 1, 2014, Pages 55-61

  Shinto, Ajit S ^a   Shibu, Deepu ^a   Kamaleshwaran, Koramadai Karuppusamy ^a   Das, Tapas ^b   Chakraborty, Sudipta ^b   Banerjee, Sharmila ^b   Thirumalaisamy, Palanisamy ^c   Das, Pravin ^d   Veersekar, Ganesh ^a  

^a KMCH   (India)

^b BHABHA ATOMIC RESEARCH CENTRE   (India)

^c Urology Clinic   (India)

^d Karuna Medical College   (India)

Author keywords

Bone pain palliation; Osseous metastases; Therapeutic radiopharmaceutical

Indexed keywords

ETHYLENEDIAMINETETRAMETHYLENE LU 177; HEMOGLOBIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; LUTETIUM ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONIC ACID; ORGANOMETALLIC COMPOUND; ORGANOPHOSPHORUS COMPOUND;

ADULT; AGED; ANALGESIA; ARTICLE; BLOOD CELL COUNT; BONE DEVELOPMENT; BONE MARROW TOXICITY; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; BREAST CANCER; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CLINICAL STUDY; DISEASE DURATION; DISSEMINATED CANCER; DISSEMINATED SKELETAL MTASTASIS; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; LUNG CANCER; MALE; PAIN ASSESSMENT; PHYSICAL PERFORMANCE; PROSTATE CANCER; QUALITY OF LIFE; RISK ASSESSMENT; THROMBOCYTE COUNT; 177LU-EDTMP; BONE PAIN PALLIATION; BONE TUMOR; METASTASIS; MIDDLE AGED; OSSEOUS METASTASES; PAIN; PATHOLOGY; SAFETY; THERAPEUTIC RADIOPHARMACEUTICAL;

177LU-EDTMP; BONE PAIN PALLIATION; OSSEOUS METASTASES; THERAPEUTIC RADIOPHARMACEUTICAL;

AGED; BONE NEOPLASMS; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PAIN; SAFETY;

EID: 84898843344     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnmt.113.132266     Document Type: Article

References (26)

1. Mertens WC et al. Systemic bone-seeking radionuclides for palliation of painful osseous metastases: current concepts. CA Cancer J Clin. 1998;48:321, 361-374.
2. McEwan AJ. Palliative therapy with bone seeking radiopharmaceuticals. Cancer Biother Radiopharm. 1998;13:413-426.
3. Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med. 2010;40:89-104.
4. Pillai MR, Chakraborty S, Das T, Venkatesh M, Ramamoorthy N. Production logistics of 177Lu for radionuclide therapy. Appl Radiat Isot. 2003;59:109-118.
5. Bijur PE, Silver W, Gallagher EJ. Reliability of the visual analog scale for measurement of acute pain. Acad Emerg Med. 2001;8:1153-1157.
6. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer. 1996;32A:1135-1141.
7. 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis. Cancer Biother Radiopharm. 2008;23:202-213.
8. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004;45:1358-1365.
9. 89Sr) chloride for palliation of painful bony metastases in cancer patients [in Japanese]. Nihon Igaku Hoshasen Gakkai Zasshi. 2005;65:399-410.
10. Das T, Pillai MR. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl Med Biol. 2013;40:23-32.
11. 153Sm-EDTMP to relieve pain from bone metastasis in lung cancer. Rev Mal Respir. 2005;22:317-320.
12. Tripathi M, Singhal T, Chandrasekhar N, et al. Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases. Indian J Cancer. 2006;43:86-92.
13. 153Sm-EDTMP for bone pain palliation in skeletal metastases. Eur J Nucl Med Mol Imaging. 2004;31(suppl 1):S171-S178.
14. Sandeman TF, Budd RS, Martin JJ. Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate. Clin Oncol (R Coll Radiol). 1992;4:160-164.
15. 177Lu-EDTMP: a potential therapeutic bone agent. Nucl Med Commun. 1998;19:587-591.
16. 177Lu-EDTMP, a potential bone pain palliation agent. Nucl Med Biol. 2010;37:215-226.
17. 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Clin Nucl Med. 2013;38:88-92.
18. Solá GA, Argüelles MG, Bottazzini DL, et al. Lutetium-177-EDTMP for bone pain palliation: preparation, biodistribution and pre-clinical studies. Radiochim Acta. 2009;88:157-161.
19. 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun. 2007;28:623-630.
20. Oosterhof GO, et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol. 2003;44:519-526.
21. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994;31:33-40.
22. Buchali K, et al. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med. 1988;14:349-351.
23. Tomblyn M, et al. The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. Cancer Control. 2012;19:137-144.
24. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43:79-86.
25. Palmedo H, Grünwald F, Wagner U, et al. Remission of bone metastases after combined chemotherapy and radionuclide therapy with Re-186 HEDP. Clin Nucl Med. 1998;23:501-504.
26. Sideras PA, Stavraka A, Gouliamos A, Limouris GS. Radionuclide therapy of painful bone metastases: a comparative study between consecutive radionuclide infusions, combination with chemotherapy, and radionuclide infusions alone-an in vivo comparison of their effectiveness. Am J Hosp Palliat Care. 2013;30:745-751.